PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
Recruiting
This is a prospective, observational cohort study. Participants with non-idiopatic pulmonary fibrosis, interstitial lung disease (ILD) will be followed for 24 months to systematically collect clinical, imaging, and biospecimen data. The primary objective is to optimize progressive pulmonary fibrosis (PPF) classification and establish PPF incidence for key ILD subtypes. Additional exploratory objectives are to 1) Prospectively validate a novel PPF classifier and assess performance durability over... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/18/2025
Locations: University of Massachusetts Chan Medical School, Worcester, Massachusetts +12 locations
Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Spine and Brain Stimulation for Movement Recovery After Cervical Spinal Cord Injury
Recruiting
Stimulation of the spinal cord and brain represents a new experimental therapy that may have potential to restore movement after spinal cord injury. While some scientists have begun to study the effect of electrical stimulation on patient's ability to walk and move their legs after lower spinal cord injury, the use of stimulation of the upper (cervical) spine to restore arm and hand function after cervical spinal cord injury remains less well explored. The investigators are doing this research s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: NewYork-Presbyterian Hospital / Columbia University Irving Medical Center (NYPH/CUIMC), New York, New York +1 locations
Conditions: Spinal Cord Injury, Spinal Cord Injury Cervical
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Recruiting
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are available but do not work the same for all patients or may stop working over time. This study will evaluate the effectiveness and adverse events of targeted therapies (TaTs) for adult participants with moderate to severe CD.... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/18/2025
Locations: Digestive Health Specialists /ID# 266216, Dothan, Alabama +222 locations
Conditions: Crohn's Disease
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
Recruiting
This study consists of two parts: phase 2 (Part A) and phase 3 (Part B). It is a multicenter study designed to evaluate the safety, effectiveness, and pharmacokinetics (PK) of CSL889 (human hemopexin) when given intravenously (IV) to adults and adolescents with sickle cell disease (SCD) experiencing vaso-occlusive crises (VOC). The main objectives of the study are to assess how CSL889 affects the time it takes for VOC to resolve in participants with SCD, and to evaluate the safety and tolerabili... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/18/2025
Locations: University of California Irvine, Orange, California +15 locations
Conditions: Sickle Cell Disease Vaso-occlusive Crisis
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 monotherapy in adult patients with selected squamous solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Providence Medical Foundation, Fullerton, California +23 locations
Conditions: Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
Brief Intervention for Chronic Pain and History of Stressful Experiences
Recruiting
The goal of this study is to understand whether a brief, three session program can be helpful in reducing symptoms related to both chronic pain and stressful experiences/trauma.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
08/18/2025
Locations: Brigham and Women's Hospital, Chestnut Hill, Massachusetts
Conditions: Chronic Pain, Trauma, Adverse Childhood Experiences
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
Recruiting
The main purpose of this study is to compare the effect of tebapivat versus placebo on anemia and to detect a dose-response for hemoglobin (Hb) response in participants with SCD.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
08/18/2025
Locations: MedStar Washington Hospital Center, Washington, District of Columbia +2 locations
Conditions: Sickle Cell Disease
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
Recruiting
The study has 2 parts, Phase 1a and Phase 1b. The goal of Phase 1a is to gather safety, PK and initial efficacy data for 225Ac-ABD147 to better understand best doses for patients with small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) of the lung following platinum-based chemotherapy. An initial group of patients will also be given an experimental imaging agent called 111In-ABD147 to help understand where ABD147 goes in the body. The goal of Phase 1b is to gather add... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Hoag Memorial Hospital Presbyterian, Newport Beach, California +4 locations
Conditions: Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Local Institution - 0136, Augusta, Georgia +143 locations
Conditions: Carcinoma, Non-Small-Cell Lung
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
Recruiting
A FIH study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VVD-130850, as single agent and in combination with checkpoint inhibition, in participants with advanced solid and hematologic tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: California Research Institute, Los Angeles, California +19 locations
Conditions: Advanced Solid Tumors, Advanced Hematologic Tumors
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Recruiting
This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes. Condition or disease Intervention/treatment Phase Advanced Solid Tumors Drug: EIK1004 (IMP1707) Phase 1/Phase 2
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
08/18/2025
Locations: Sarah Cannon Research Institute at HealthOne, Denver, Colorado +9 locations
Conditions: Advanced Solid Tumors
An Open Label Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacologic Properties of High Dose Ambroxol Hydrochloride in Adult (≥ 18 Years of Age) Subjects With MPS III
Recruiting
A dose escalation study to evaluate the safety, tolerability, and pharmacologic properties of Ambroxol in adult participants with Sanfilippo disease(s) (MPS3).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/18/2025
Locations: Lysosomal & Rare Disorders Research & Treatment Center, Inc., Fairfax, Virginia
Conditions: Sanfilippo Syndrome, MPS3